敗血症診断市場- 世界の産業規模、シェア、動向、機会、予測、技術別、製品別、診断方法別、病原体別、地域別、競合別、2020-2030年

敗血症診断の世界市場は、2024年には6億1,225万米ドルと評価され、2030年には9億5,418万米ドルに達すると予測され、予測期間中のCAGRは7.68%で成長します。

敗血症は、感染に対する免疫反応の不均衡から生じる、生命を脅かす重篤な病態であり、全身性の炎症と臓器不全を引き起こす可能性があります。患者の生存率を高め、合併症を予防するためには、迅速な診断と治療が不可欠です。世界の敗血症の罹患率の増加、ヘルスケア専門家や一般市民の意識の高まりが、迅速で正確な診断ソリューションの需要を牽引しています。敗血症診断は、分子技術、免疫測定法、自動血液培養システムの進歩により大きく進化しています。これらの技術は、病原体の早期発見と特定を可能にし、タイムリーな治療介入を可能にします。高齢化社会における感染症への感受性の高まりは、入院患者の増加とともに、市場の成長にさらに寄与しています。ヘルスケアシステムが早期の敗血症管理を優先する中、効率的な診断ツールの需要は、技術革新と継続的な研究開発努力によって後押しされ、成長を続けています。

市場促進要因

敗血症診断技術の進歩

主な市場課題

ジェネリック医薬品の競合

主要市場動向

バイオマーカーの発見

目次

第1章 概要

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 顧客の声

第5章 世界の敗血症診断市場展望

• 市場規模・予測
  • 金額別
• 市場シェア・予測
  • 技術別（分子診断、微生物学、免疫測定、その他の技術）
  • 製品別（機器、アッセイおよび試薬、その他の製品）
  • 診断方法別（従来の診断と自動診断）
  • 病原体別（細菌性敗血症、真菌性敗血症、その他の病原体）
  • 地域別
  • 企業別（2024）
• 市場マップ

第6章 北米の敗血症診断市場展望

• 市場規模・予測
• 市場シェア・予測
• 北米：国別分析
  • 米国
  • カナダ
  • メキシコ

第7章 欧州の敗血症診断市場展望

• 市場規模・予測
• 市場シェア・予測
• 欧州：国別分析
  • ドイツ
  • 英国
  • イタリア
  • フランス
  • スペイン

第8章 アジア太平洋地域の敗血症診断市場展望

• 市場規模・予測
• 市場シェア・予測
• アジア太平洋地域：国別分析
  • 中国
  • インド
  • 日本
  • 韓国
  • オーストラリア

第9章 南米の敗血症診断市場展望

• 市場規模・予測
• 市場シェア・予測
• 南米：国別分析
  • ブラジル
  • アルゼンチン
  • コロンビア

第10章 中東・アフリカの敗血症診断市場展望

• 市場規模・予測
• 市場シェア・予測
• 中東・アフリカ：国別分析
  • 南アフリカ
  • サウジアラビア
  • アラブ首長国連邦

第11章 市場力学

• 促進要因
• 課題

第12章 市場動向と発展

• 最近の動向
• 合併と買収

第13章 世界の敗血症診断市場：SWOT分析

第14章 ポーターのファイブフォース分析

• 業界内の競合
• 新規参入の可能性
• サプライヤーの力
• 顧客の力
• 代替治療法の脅威

第15章 競合情勢

• Abbott Laboratories Inc.
• DiaSorin SpA
• Becton, Dickinson and Company
• BioMerieux Inc.
• F. Hoffmann-La Roche AG
• Danaher Corporation
• Thermo Fisher Scientific Inc
• Siemens Healthineers AG
• Seegene, Inc.
• Roche Diagnostics Corporation

第16章 戦略的提言

第17章 調査会社について・免責事項

The Global Sepsis Diagnostics Market was valued at USD 612.25 Million in 2024 and is projected to reach USD 954.18 Million by 2030, growing at a CAGR of 7.68% during the forecast period. Sepsis is a critical, life-threatening condition resulting from an imbalanced immune response to infection, leading to systemic inflammation and potential organ failure. Prompt diagnosis and treatment are essential to improve patient survival and prevent complications. The growing incidence of sepsis globally, coupled with heightened awareness among healthcare professionals and the public, is driving the demand for rapid and accurate diagnostic solutions. Sepsis diagnostics have evolved significantly with advancements in molecular techniques, immunoassays, and automated blood culture systems. These technologies allow earlier detection and pathogen identification, enabling timely therapeutic interventions. The increasing susceptibility of the aging population to infections, along with rising hospital admissions, further contributes to market growth. As healthcare systems prioritize early sepsis management, the demand for efficient diagnostic tools continues to grow, bolstered by innovation and ongoing R&D efforts.

Key Market Drivers

Advancements in Sepsis Diagnostic Technologies

Technological innovation has played a central role in transforming sepsis diagnosis, significantly enhancing accuracy and speed. Key advancements include the use of polymerase chain reaction (PCR) for the rapid identification of microbial DNA or RNA, and next-generation sequencing (NGS), which offers comprehensive pathogen detection in a single test. Automated blood culture systems and antibiotic-neutralizing blood culture bottles have improved diagnostic reliability in septic patients undergoing antimicrobial treatment. Additionally, the development of immunoassays for biomarkers such as procalcitonin (PCT) and C-reactive protein (CRP) enables clinicians to assess infection severity and guide treatment decisions. Lateral flow assays now allow point-of-care testing for quicker triage. Host gene expression analysis and emerging microRNA biomarkers also show promise in distinguishing sepsis from other inflammatory conditions. These innovations are enabling faster clinical decision-making, reducing mortality, and expanding the sepsis diagnostics landscape.

Key Market Challenges

Generic Competition

The emergence of generic alternatives in the diagnostic sector presents a significant challenge for established players in the sepsis diagnostics market. Once patent protections expire, generic manufacturers often introduce cost-effective diagnostic solutions that create pricing pressure and reduce profit margins for original manufacturers. This market dynamic forces branded companies to adopt more competitive pricing strategies, potentially affecting their revenue streams. Moreover, the widespread availability of generics can reduce the market share of innovative firms and discourage future investments in R&D, slowing the pace of diagnostic innovation. Ensuring the quality and accuracy of generic diagnostics remains a concern, prompting the need for strict regulatory oversight. Despite offering affordability, generics can disrupt established business models, compelling original manufacturers to differentiate through technological enhancements or value-added services.

Key Market Trends

Biomarker Discovery

Biomarker discovery is rapidly shaping the future of sepsis diagnostics, offering improved precision and speed in identifying and managing the condition. Biomarkers provide specific biological indicators that help differentiate sepsis from other inflammatory or infectious conditions. Their use enables more accurate and earlier diagnoses, which are crucial for timely intervention. Biomarkers such as procalcitonin, CRP, and cytokine profiles are increasingly used to assess infection severity and monitor treatment responses. Additionally, the development of multiplex assays that simultaneously evaluate multiple biomarkers is enhancing diagnostic accuracy. The rise of microRNA profiling and host gene expression analysis is further expanding the biomarker toolkit, allowing for personalized diagnostic approaches. These innovations support the shift toward precision medicine in sepsis care, facilitating targeted and effective treatment strategies. The growing pipeline of biomarker-based tests is expected to fuel market growth by providing clinicians with reliable tools to improve patient outcomes.

Key Market Players

• Abbott Laboratories
• DiaSorin SpA
• Becton, Dickinson, and Company
• BioMerieux Inc.
• F. Hoffmann-La Roche AG
• Danaher Corporation
• Thermo Fisher Scientific Inc
• Siemens Healthineers AG
• Seegene, Inc.
• Roche Diagnostics Corporation

Report Scope:

In this report, the Global Sepsis Diagnostics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Sepsis Diagnostics Market, By Technology:

• Molecular Diagnostics
• Microbiology
• Immunoassay
• Other Technologies

Sepsis Diagnostics Market, By Product:

• Instruments
• Assays and Reagents
• Other Products

Sepsis Diagnostics Market, By Diagnostic Method:

• Conventional Diagnostics
• Automated Diagnostics

Sepsis Diagnostics Market, By Pathogen:

• Bacterial Sepsis
• Fungal Sepsis
• Other Pathogens

Sepsis Diagnostics Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Asia-Pacific
  • China
  • India
  • South Korea
  • Australia
  • Japan
• Europe
  • Germany
  • France
  • United Kingdom
  • Spain
  • Italy
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Sepsis Diagnostics Market.

Available Customizations:

Global Sepsis Diagnostics Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validations
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Sepsis Diagnostics Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Technology (Molecular Diagnostics, Microbiology, Immunoassay, and Other Technologies)
  • 5.2.2. By Product (Instruments, Assays and Reagents, and Other Products)
  • 5.2.3. By Diagnostic Method (Conventional Diagnostics and Automated Diagnostics)
  • 5.2.4. By Pathogen (Bacterial Sepsis, Fungal Sepsis, and Other Pathogens)
  • 5.2.5. By Region
  • 5.2.6. By Company (2024)
• 5.3. Market Map

6. North America Sepsis Diagnostics Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Technology
  • 6.2.2. By Product
  • 6.2.3. By Diagnostic Method
  • 6.2.4. By Pathogen
  • 6.2.5. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Sepsis Diagnostics Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Technology
      • 6.3.1.2.2. By Product
      • 6.3.1.2.3. By Diagnostic Method
      • 6.3.1.2.4. By Pathogen
  • 6.3.2. Canada Sepsis Diagnostics Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Technology
      • 6.3.2.2.2. By Product
      • 6.3.2.2.3. By Diagnostic Method
      • 6.3.2.2.4. By Pathogen
  • 6.3.3. Mexico Sepsis Diagnostics Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Technology
      • 6.3.3.2.2. By Product
      • 6.3.3.2.3. By Diagnostic Method
      • 6.3.3.2.4. By Pathogen

7. Europe Sepsis Diagnostics Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Technology
  • 7.2.2. By Product
  • 7.2.3. By Diagnostic Method
  • 7.2.4. By Pathogen
  • 7.2.5. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Sepsis Diagnostics Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Technology
      • 7.3.1.2.2. By Product
      • 7.3.1.2.3. By Diagnostic Method
      • 7.3.1.2.4. By Pathogen
  • 7.3.2. United Kingdom Sepsis Diagnostics Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Technology
      • 7.3.2.2.2. By Product
      • 7.3.2.2.3. By Diagnostic Method
      • 7.3.2.2.4. By Pathogen
  • 7.3.3. Italy Sepsis Diagnostics Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Technology
      • 7.3.3.2.2. By Product
      • 7.3.3.2.3. By Diagnostic Method
      • 7.3.3.2.4. By Pathogen
  • 7.3.4. France Sepsis Diagnostics Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Technology
      • 7.3.4.2.2. By Product
      • 7.3.4.2.3. By Diagnostic Method
      • 7.3.4.2.4. By Pathogen
  • 7.3.5. Spain Sepsis Diagnostics Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Technology
      • 7.3.5.2.2. By Product
      • 7.3.5.2.3. By Diagnostic Method
      • 7.3.5.2.4. By Pathogen

8. Asia-Pacific Sepsis Diagnostics Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Technology
  • 8.2.2. By Product
  • 8.2.3. By Diagnostic Method
  • 8.2.4. By Pathogen
  • 8.2.5. By Country
• 8.3. Asia-Pacific: Country Analysis
  • 8.3.1. China Sepsis Diagnostics Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Technology
      • 8.3.1.2.2. By Product
      • 8.3.1.2.3. By Diagnostic Method
      • 8.3.1.2.4. By Pathogen
  • 8.3.2. India Sepsis Diagnostics Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Technology
      • 8.3.2.2.2. By Product
      • 8.3.2.2.3. By Diagnostic Method
      • 8.3.2.2.4. By Pathogen
  • 8.3.3. Japan Sepsis Diagnostics Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Technology
      • 8.3.3.2.2. By Product
      • 8.3.3.2.3. By Diagnostic Method
      • 8.3.3.2.4. By Pathogen
  • 8.3.4. South Korea Sepsis Diagnostics Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Technology
      • 8.3.4.2.2. By Product
      • 8.3.4.2.3. By Diagnostic Method
      • 8.3.4.2.4. By Pathogen
  • 8.3.5. Australia Sepsis Diagnostics Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Technology
      • 8.3.5.2.2. By Product
      • 8.3.5.2.3. By Diagnostic Method
      • 8.3.5.2.4. By Pathogen

9. South America Sepsis Diagnostics Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Technology
  • 9.2.2. By Product
  • 9.2.3. By Diagnostic Method
  • 9.2.4. By Pathogen
  • 9.2.5. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Sepsis Diagnostics Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Technology
      • 9.3.1.2.2. By Product
      • 9.3.1.2.3. By Diagnostic Method
      • 9.3.1.2.4. By Pathogen
  • 9.3.2. Argentina Sepsis Diagnostics Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Technology
      • 9.3.2.2.2. By Product
      • 9.3.2.2.3. By Diagnostic Method
      • 9.3.2.2.4. By Pathogen
  • 9.3.3. Colombia Sepsis Diagnostics Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Technology
      • 9.3.3.2.2. By Product
      • 9.3.3.2.3. By Diagnostic Method
      • 9.3.3.2.4. By Pathogen

10. Middle East and Africa Sepsis Diagnostics Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Technology
  • 10.2.2. By Product
  • 10.2.3. By Diagnostic Method
  • 10.2.4. By Pathogen
  • 10.2.5. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Sepsis Diagnostics Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Technology
      • 10.3.1.2.2. By Product
      • 10.3.1.2.3. By Diagnostic Method
      • 10.3.1.2.4. By Pathogen
  • 10.3.2. Saudi Arabia Sepsis Diagnostics Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Technology
      • 10.3.2.2.2. By Product
      • 10.3.2.2.3. By Diagnostic Method
      • 10.3.2.2.4. By Pathogen
  • 10.3.3. UAE Sepsis Diagnostics Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Technology
      • 10.3.3.2.2. By Product
      • 10.3.3.2.3. By Diagnostic Method
      • 10.3.3.2.4. By Pathogen

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Recent Development
• 12.2. Mergers & Acquisitions

13. Global Sepsis Diagnostics Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Treatment Types

15. Competitive Landscape

• 15.1. Abbott Laboratories Inc.
  • 15.1.1. Business Overview
  • 15.1.2. Company Snapshot
  • 15.1.3. Products & Services
  • 15.1.4. Financials (As Reported)
  • 15.1.5. Recent Developments
  • 15.1.6. Key Personnel Details
  • 15.1.7. SWOT Analysis
• 15.2. DiaSorin SpA
• 15.3. Becton, Dickinson and Company
• 15.4. BioMerieux Inc.
• 15.5. F. Hoffmann-La Roche AG
• 15.6. Danaher Corporation
• 15.7. Thermo Fisher Scientific Inc
• 15.8. Siemens Healthineers AG
• 15.9. Seegene, Inc.
• 15.10. Roche Diagnostics Corporation

16. Strategic Recommendations

17. About Us & Disclaimer